Johan Bodegård

  • Epidemiologist MD PhD
Johan Bodegård completed his thesis on the OIS cohort in 2006. After working as an MD at Akershus University Hospital for some years he has now moved on the AstraZeneca where he holds a position as an epidemiologist. Dr. Bodegård has been instrumental to the collection of mortality and morbidity data and has contributed to a large number of OIS publications.
 

Author network for Johan Bodegård by COREMINE medical


Publications 2018

Cavender MA, Norhammar A, Birkeland KI, Jørgensen ME, Wilding JP, Khunti K, Fu AZ, Bodegård J, Blak BT, Wittbrodt E, Thuresson M, Fenici P, Hammar N, Kosiborod M, CVD-REAL Investigators and Study Group (2018)
SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL
J Am Coll Cardiol, 71 (22), 2497-2506
DOI 10.1016/j.jacc.2018.01.085, PubMed 29852973

Engeseth K, Prestgaard EE, Mariampillai JE, Grundvold I, Liestol K, Kjeldsen SE, Bodegard J, Erikssen JE, Gjesdal K, Skretteberg PT (2018)
Physical fitness is a modifiable predictor of early cardiovascular death: A 35-year follow-up study of 2014 healthy middle-aged men
Eur J Prev Cardiol, 25 (15), 1655-1663
DOI 10.1177/2047487318793459, PubMed 30103630

Farkhooy A, Bodegård J, Erikssen JE, Janson C, Hedenström H, Stavem K, Malinovschi A (2018)
Cross-sectional and longitudinal analyses of the association between lung function and exercise capacity in healthy Norwegian men
BMC Pulm Med, 18 (1), 118
DOI 10.1186/s12890-018-0655-z, PubMed 30021542

Kosiborod M, Birkeland KI, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Jørgensen ME, Wittbrodt ET, Thuresson M, Bodegård J, Hammar N, Fenici P, CVD-REAL Investigators and Study Group (2018)
Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study
Diabetes Obes Metab, 20 (8), 1983-1987
DOI 10.1111/dom.13299, PubMed 29569378

Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P, CVD-REAL Investigators and Study Group (2018)
Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)"
Circulation, 137 (9), 989-991
DOI 10.1161/CIRCULATIONAHA.117.031847, PubMed 29483180

Mariampillai JE, Prestgaard EE, Kjeldsen SE, Liestøl K, Engeseth K, Erikssen J, Bodegard J, Berge E, Grundvold I, Skretteberg PT (2018)
SBP above 180 mmHg at moderate exercise workload increases coronary heart disease risk in healthy men during 28-year follow-up
J Hypertens (in press)
DOI 10.1097/HJH.0000000000001959, PubMed 30325341

Nathanson D, Sabale U, Eriksson JW, Nyström T, Norhammar A, Olsson U, Bodegård J (2018)
Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006-2014
Pharmacoecon Open, 2 (4), 393-402
DOI 10.1007/s41669-017-0063-y, PubMed 29623637

Nyström T, Bodegård J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW (2018)
Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10
Diabetes Care, 41 (6), e104-e105
DOI 10.2337/dc18-0339, PubMed 29784707

Publications 2017

Birkeland KI, Jørgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Nyström T, Eriksson JW, Bodegård J, Norhammar A (2017)
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
Lancet Diabetes Endocrinol, 5 (9), 709-717
DOI 10.1016/S2213-8587(17)30258-9, PubMed 28781064

Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P, CVD-REAL Investigators and Study Group* (2017)
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)
Circulation, 136 (3), 249-259
DOI 10.1161/CIRCULATIONAHA.117.029190, PubMed 28522450

Mariampillai JE, Engeseth K, Kjeldsen SE, Grundvold I, Liestøl K, Erikssen G, Erikssen J, Bodegard J, Skretteberg PT (2017)
Exercise systolic blood pressure at moderate workload predicts cardiovascular disease and mortality through 35 years of follow-up in healthy, middle-aged men
Blood Press, 26 (4), 229-236
DOI 10.1080/08037051.2017.1291276, PubMed 28276720

Nyström T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW (2017)
Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes
Diabetes Obes Metab, 19 (6), 831-841
DOI 10.1111/dom.12889, PubMed 28116795

Persson F, Nyström T, Jørgensen ME, Carstensen B, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Eriksson JW, Norhammar A, Bodegard J, Birkeland KI (2017)
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study
Diabetes Obes Metab, 20 (2), 344-351
DOI 10.1111/dom.13077, PubMed 28771923

Prestgaard E, Hodnesdal C, Engeseth K, Erikssen J, Bodegård J, Liestøl K, Gjesdal K, Kjeldsen SE, Grundvold I, Berge E (2017)
Long-term predictors of stroke in healthy middle-aged men
Int J Stroke, 13 (3), 292-300
DOI 10.1177/1747493017730760, PubMed 28929941

Sabale U, Bodegard J, Svennblad B, Östgren CJ, Johansson G, Ekman M, Henriksson M, Nilsson P (2017)
Weight change patterns and healthcare costs in patients with newly-diagnosed type-2 diabetes in Sweden
Prim Care Diabetes, 11 (3), 217-225
DOI 10.1016/j.pcd.2017.03.001, PubMed 28389199

Publications 2016

Engeseth K, Hodnesdal C, Grundvold I, Liestøl K, Gjesdal K, Kjeldsen SE, Erikssen JE, Bodegard J, Skretteberg PT (2016)
Temporal Reduction in Chronotropic Index Predicts Risk of Cardiovascular Death Among Healthy Middle-Aged Men: a 28-Year Follow-Up Study
J Am Heart Assoc, 5 (12)
DOI 10.1161/JAHA.116.004555, PubMed 27881424

Eriksson JW, Bodegard J, Nathanson D, Thuresson M, Nyström T, Norhammar A (2016)
Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality
Diabetes Res Clin Pract, 117, 39-47
DOI 10.1016/j.diabres.2016.04.055, PubMed 27329021

Hasvold P, Thuresson M, Sundström J, Hammar N, Kjeldsen SE, Johansson G, Holme I, Bodegård J (2016)
Association Between Paradoxical HDL Cholesterol Decrease and Risk of Major Adverse Cardiovascular Events in Patients Initiated on Statin Treatment in a Primary Care Setting
Clin Drug Investig, 36 (3), 225-33
DOI 10.1007/s40261-015-0372-9, PubMed 26718960

Johnston N, Bodegard J, Jerström S, Åkesson J, Brorsson H, Alfredsson J, Albertsson PA, Karlsson JE, Varenhorst C (2016)
Effects of interactive patient smartphone support app on drug adherence and lifestyle changes in myocardial infarction patients: A randomized study
Am Heart J, 178, 85-94
DOI 10.1016/j.ahj.2016.05.005, PubMed 27502855

Kalkan A, Bodegard J, Sundström J, Svennblad B, Östgren CJ, Nilsson PN, Johansson G, Ekman M (2016)
Increased healthcare utilization costs following initiation of insulin treatment in type 2 diabetes: A long-term follow-up in clinical practice
Prim Care Diabetes, 11 (2), 184-192
DOI 10.1016/j.pcd.2016.11.002, PubMed 27894781

Norhammar A, Bodegård J, Nyström T, Thuresson M, Eriksson JW, Nathanson D (2016)
Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006-2013
Diabetologia, 59 (8), 1692-701
DOI 10.1007/s00125-016-3971-y, PubMed 27189067

Nyström T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW (2016)
Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia
Diabetes Res Clin Pract, 123, 199-208
DOI 10.1016/j.diabres.2016.12.004, PubMed 28056431

Publications 2015

Carlborg A, Thuresson M, Ferntoft L, Bodegard J (2015)
Characteristics of bipolar disorder patients treated with immediate- and extended-release quetiapine in a real clinical setting: a longitudinal, cohort study of 1761 patients
Ther Adv Psychopharmacol, 5 (1), 13-21
DOI 10.1177/2045125314560740, PubMed 25653826

Grundvold I, Bodegard J, Nilsson PM, Svennblad B, Johansson G, Östgren CJ, Sundström J (2015)
Body weight and risk of atrial fibrillation in 7,169 patients with newly diagnosed type 2 diabetes; an observational study
Cardiovasc Diabetol, 14, 5
DOI 10.1186/s12933-014-0170-3, PubMed 25589001

Lindh A, Persson F, Sobocki P, Bodegard J, Lindarck N (2015)
Nordic Longitudinal Data from Electronic Medical Records and Full Population National Registers: Unique Opportunities for New Insights in Benefit of Diabetes Patients
Value Health, 18 (7), A726
DOI 10.1016/j.jval.2015.09.2760, PubMed 26534068

Sabale U, Bodegård J, Sundström J, Östgren CJ, Nilsson P, Johansson G, Svennblad B, Henriksson M (2015)
Healthcare utilization and costs following newly diagnosed type-2 diabetes in Sweden: A follow-up of 38,956 patients in a clinical practice setting
Prim Care Diabetes, 9 (5), 330-7
DOI 10.1016/j.pcd.2015.01.001, PubMed 25631469

Publications 2014

Carlborg A, Ferntoft L, Thuresson M, Bodegard J (2014)
Population study of disease burden, management, and treatment of bipolar disorder in Sweden: a retrospective observational registry study
Bipolar Disord, 17 (1), 76-85
DOI 10.1111/bdi.12234, PubMed 25056132

Engeseth K, Hodnesdal C, Grundvold I, Liestøl K, Gjesdal K, Erikssen G, Kjeldsen SE, Erikssen JE, Bodegard J, Skretteberg PT (2014)
Heart rate reserve predicts cardiovascular death among physically unfit but otherwise healthy middle-aged men: a 35-year follow-up study
Eur J Prev Cardiol, 23 (1), 59-66
DOI 10.1177/2047487314553202, PubMed 25281482

Hasvold LP, Bodegård J, Thuresson M, Stålhammar J, Hammar N, Sundström J, Russell D, Kjeldsen SE (2014)
Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15,990 patients
J Hum Hypertens, 28 (11), 663-9
DOI 10.1038/jhh.2014.43, PubMed 25211055

Sabale U, Bodegård J, Sundström J, Svennblad B, Östgren CJ, Nilsson P, Johansson G, Henriksson M (2014)
Association of Changes In Body Weight With Health Care Costs Among Patients With Newly-Diagnosed Type-2 Diabetes In Sweden
Value Health, 17 (7), A338
DOI 10.1016/j.jval.2014.08.660, PubMed 27200610

Publications 2013

Bodegard J, Sundström J, Svennblad B, Östgren CJ, Nilsson PM, Johansson G (2013)
Changes in body mass index following newly diagnosed type 2 diabetes and risk of cardiovascular mortality: a cohort study of 8486 primary-care patients
Diabetes Metab, 39 (4), 306-13
DOI 10.1016/j.diabet.2013.05.004, PubMed 23871502

Grundvold I, Skretteberg PT, Engeseth K, Gjesdal K, Kjeldsen SE, Arnesen H, Bodegard J, Liestøl K, Erikssen G, Erikssen J (2013)
Response to Letter by Morris et al regarding article, "Low heart rates predict incident atrial fibrillation in healthy middle-aged men" by Grundvold et al
Circ Arrhythm Electrophysiol, 6 (6), e102
DOI 10.1161/CIRCEP.113.001154, PubMed 24347602

Grundvold I, Skretteberg PT, Liestøl K, Erikssen G, Engeseth K, Gjesdal K, Kjeldsen SE, Arnesen H, Erikssen J, Bodegard J (2013)
Low heart rates predict incident atrial fibrillation in healthy middle-aged men
Circ Arrhythm Electrophysiol, 6 (4), 726-31
DOI 10.1161/CIRCEP.113.000267, PubMed 23873309

Hedberg J, Sundström J, Thuresson M, Aarskog P, Oldgren J, Bodegard J (2013)
Low-dose acetylsalicylic acid and gastrointestinal ulcers or bleeding--a cohort study of the effects of proton pump inhibitor use patterns
J Intern Med, 274 (4), 371-80
DOI 10.1111/joim.12103, PubMed 23800296

Skretteberg PT, Grundvold I, Kjeldsen SE, Engeseth K, Liestøl K, Erikssen G, Erikssen J, Gjesdal K, Bodegard J (2013)
Seven-year increase in exercise systolic blood pressure at moderate workload predicts long-term risk of coronary heart disease and mortality in healthy middle-aged men
Hypertension, 61 (5), 1134-40
DOI 10.1161/HYPERTENSIONAHA.111.00793, PubMed 23529164

Skretteberg PT, Grytten AN, Gjertsen K, Grundvold I, Kjeldsen SE, Erikssen J, Mellbin L, Liestøl K, Fraser DA, Erikssen G, Pedersen TR, Bodegard J (2013)
Triglycerides-diabetes association in healthy middle-aged men: modified by physical fitness? A long term follow-up of 1962 Norwegian men in the Oslo Ischemia Study
Diabetes Res Clin Pract, 101 (2), 201-9
DOI 10.1016/j.diabres.2013.06.001, PubMed 23827210

Sundström J, Sheikhi R, Ostgren CJ, Svennblad B, Bodegård J, Nilsson PM, Johansson G (2013)
Blood pressure levels and risk of cardiovascular events and mortality in type-2 diabetes: cohort study of 34 009 primary care patients
J Hypertens, 31 (8), 1603-10
DOI 10.1097/HJH.0b013e32836123aa, PubMed 23625112

Publications 2012

Grundvold I, Skretteberg PT, Liestøl K, Erikssen G, Kjeldsen SE, Arnesen H, Erikssen J, Bodegard J (2012)
Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men: a 35-year follow-up study
Hypertension, 59 (2), 198-204
DOI 10.1161/HYPERTENSIONAHA.111.179713, PubMed 22252392

Grundvold I, Skretteberg PT, Liestøl K, Gjesdal K, Erikssen G, Kjeldsen SE, Arnesen H, Erikssen J, Bodegard J (2012)
Importance of physical fitness on predictive effect of body mass index and weight gain on incident atrial fibrillation in healthy middle-age men
Am J Cardiol, 110 (3), 425-32
DOI 10.1016/j.amjcard.2012.03.043, PubMed 22579085

Hodnesdal C, Prestgaard E, Erikssen G, Gjesdal K, Kjeldsen SE, Liestol K, Skretteberg PT, Erikssen J, Bodegard J (2012)
Rapidly upsloping ST-segment on exercise ECG: a marker of reduced coronary heart disease mortality risk
Eur J Prev Cardiol, 20 (4), 541-8
DOI 10.1177/2047487312444370, PubMed 22492865

Publications 2011

Bodegard J, Skretteberg PT, Gjesdal K, Pyörälä K, Kjeldsen SE, Liestøl K, Erikssen G, Erikssen J (2011)
Low-grade systolic murmurs in healthy middle-aged individuals: innocent or clinically significant? A 35-year follow-up study of 2014 Norwegian men
J Intern Med, 271 (6), 581-8
DOI 10.1111/j.1365-2796.2011.02480.x, PubMed 22061296

Skretteberg PT, Grundvold I, Kjeldsen SE, Erikssen JE, Sandvik L, Liestøl K, Erikssen G, Pedersen TR, Bodegard J (2011)
HDL-cholesterol and prediction of coronary heart disease: modified by physical fitness? A 28-year follow-up of apparently healthy men
Atherosclerosis, 220 (1), 250-6
DOI 10.1016/j.atherosclerosis.2011.10.009, PubMed 22062589

Publications 2010

Henriksson M, Russell D, Bodegard J, Kjeldsen S, Hasvold P, Stålhammar J, Levin LÅ (2010)
Health-care costs of losartan and candesartan in the primary treatment of hypertension
J Hum Hypertens, 25 (2), 130-6
DOI 10.1038/jhh.2010.36, PubMed 20376078

Russell D, Stålhammar J, Bodegard J, Hasvold P, Thuresson M, Kjeldsen SE (2010)
Cardiovascular events in subgroups of patients during primary treatment of hypertension with candesartan or losartan
J Clin Hypertens (Greenwich), 13 (3), 189-97
DOI 10.1111/j.1751-7176.2010.00410.x, PubMed 21366850

Skretteberg PT, Bodegård J, Kjeldsen SE, Erikssen G, Thaulow E, Sandvik L, Erikssen JE (2010)
Interaction between inflammation and blood viscosity predicts cardiovascular mortality
Scand Cardiovasc J, 44 (2), 107-12
DOI 10.1080/14017430903171248, PubMed 19670036

Publications 2009

Kjeldsen SE, Stålhammar J, Hasvold P, Bodegard J, Olsson U, Russell D (2009)
Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension
J Hum Hypertens, 24 (4), 263-73
DOI 10.1038/jhh.2009.77, PubMed 19890371

Publications 2005

Bodegard J, Erikssen G, Bjørnholt JV, Gjesdal K, Liestøl K, Erikssen J (2005)
Reasons for terminating an exercise test provide independent prognostic information: 2014 apparently healthy men followed for 26 years
Eur Heart J, 26 (14), 1394-401
DOI 10.1093/eurheartj/ehi278, PubMed 15855193

Gulati G, Bodegard J (2005)
[Long term prognosis in relation to the presence of systolic heart murmurs in healthy middle-aged men]
Tidsskr Nor Laegeforen, 125 (9), 1157-8
PubMed 15880150

Publications 2004

Bodegard J, Erikssen G, Bjornholt JV, Thelle D, Erikssen J (2004)
Possible angina detected by the WHO angina questionnaire in apparently healthy men with a normal exercise ECG: coronary heart disease or not? A 26 year follow up study
Heart, 90 (6), 627-32
DOI 10.1136/hrt.2003.012542, PubMed 15145862

Bodegard J, Erikssen G, Bjørnholt JV, Gjesdal K, Thelle D, Erikssen J (2004)
Symptom-limited exercise testing, ST depressions and long-term coronary heart disease mortality in apparently healthy middle-aged men
Eur J Cardiovasc Prev Rehabil, 11 (4), 320-7
DOI 10.1097/01.hjr.0000136460.57921.46, PubMed 15292766

Erikssen G, Bodegard J, Bjørnholt JV, Liestøl K, Thelle DS, Erikssen J (2004)
Exercise testing of healthy men in a new perspective: from diagnosis to prognosis
Eur Heart J, 25 (11), 978-86
DOI 10.1016/j.ehj.2004.04.009, PubMed 15172470

Erikssen G, Bodegard J, Erikssen J (2004)
[Exercise ECG]
Tidsskr Nor Laegeforen, 124 (3), 339-41
PubMed 14963507

Publications 2003

Bjørnholt JV, Erikssen G, Kjeldsen SE, Bodegård J, Thaulow E, Erikssen J (2003)
Fasting blood glucose is independently associated with resting and exercise blood pressures and development of elevated blood pressure
J Hypertens, 21 (7), 1383-9
DOI 10.1097/01.hjh.0000059085.43904.cc, PubMed 12817188

Publications 2002

Bodegard J, Erikssen G, Sandvik L, Kjeldsen SE, Bjørnholt J, Erikssen JE (2002)
Early versus late morning measurement of blood pressure in healthy men. A potential source of measurement bias?
Blood Press, 11 (6), 366-70
DOI 10.1080/080370502321095339, PubMed 12523680

Page visits: 128